-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Bao Pharma says FDA clears IND for KJ015 anti-HER2 bispecific antibody injection

PUBT·08/24/2026 10:01:20
Listen to the news
Shanghai Bao Pharma says FDA clears IND for KJ015 anti-HER2 bispecific antibody injection
  • Shanghai Bao Pharmaceuticals won US FDA clearance on Aug. 21, 2026 to start US clinical trials of KJ015.
  • KJ015 is a subcutaneous anti-HER2 bispecific antibody injection.
  • The drug already has China IND clearance; a Phase I trial began in June 2025, with completion expected in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260824-12296359), on August 24, 2026, and is solely responsible for the information contained therein.